Target Information

Target General Infomation
Target ID
T20978
Former ID
TTDI01957
Target Name
T-cell surface glycoprotein CD8
Target Type
Clinical Trial
Disease Cancer [ICD9: 140-229; ICD10: C00-C96]
Human immunodeficiency virus infection [ICD9: 279.3; ICD10: B20-B26]
Influenza virus [ICD10: J11.1]
Function
Identifies cytotoxic/suppressor T-cells that interact with MHC class I bearing targets. CD8 is thought to play a role in the process of T-cell mediated killing. CD8 alpha chains binds to class I MHC molecules alpha-3 domains.
Drugs and Mode of Action
Drug(s) Fluoropeptide vaccine Drug Info Phase 2 Influenza virus [524093]
Anti-VEGFR2 CD8 cell therapy Drug Info Phase 1/2 Cancer [523207]
LIPO-4 Drug Info Phase 1 Human immunodeficiency virus infection [521652]
Protein vaccines Drug Info Phase 1 Cancer [551003]
Modulator Anti-VEGFR2 CD8 cell therapy Drug Info [523207], [532072]
Pathways
KEGG Pathway Cell adhesion molecules (CAMs)
Antigen processing and presentation
Hematopoietic cell lineage
T cell receptor signaling pathway
Primary immunodeficiency
References
Ref 521652ClinicalTrials.gov (NCT00121121) Safety of Intradermal Versus Intramuscular Administration of HIV Lipopeptides in HIV Uninfected Adult Volunteers. U.S. National Institutes of Health.
Ref 523207ClinicalTrials.gov (NCT01218867) CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer. U.S. National Institutes of Health.
Ref 524093ClinicalTrials.gov (NCT01703923) An Exploratory Study of FP01 Lozenges in Subjects With Chronic Refractory Cough. U.S. National Institutes of Health.
Ref 551003Clinical pipeline report, company report or official report of ImmunoFrontier Inc.
Ref 523207ClinicalTrials.gov (NCT01218867) CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer. U.S. National Institutes of Health.
Ref 526971Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients. J Immunol. 2004 Mar 1;172(5):3289-96.
Ref 532072Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci U S A. 2012 Oct 23;109(43):17561-6.
Ref 532427Long-term CD4(+) and CD8(+) T-cell responses induced in HIV-uninfected volunteers following intradermal or intramuscular administration of an HIV-lipopeptide vaccine (ANRS VAC16). Vaccine. 2013 Sep 13;31(40):4406-15.
Ref 532845A novel peptide-based pan-influenza A vaccine: a double blind, randomised clinical trial of immunogenicity and safety. Vaccine. 2015 Jan 3;33(2):396-402.

If you find any error in data or bug in web service, please kindly report it to Dr. Tang and Dr. Mou.